Is there rationale for WHO shifting investment from infectious to NCDs?

Is there rationale for WHO shifting investment from infectious to NCDs?

Is there rationale for WHO shifting investment from infectious to NCDs?

 Introduction

This blog entry will try and elucidate the shift in investment from infectious to non-communicable diseases by the World Health Organisation (WHO) drawing successes from the Millennium Development Goals 6: “To combat HIV/AIDS, malaria, and other diseases”. Initially this blog entry will provide an overview of the management strategies and progress that has been made in addressing infectious diseases (using the “big three diseases” of the MDG 6 as examples). It will then highlight the financial investment from the different Global Health Actors towards these ‘big 3 diseases’ as compared to the other diseases and in conclusion determine if the WHO shift in investment is justifiable or not.

The term ‘infectious diseases’ (IDs) does not refer to a homogeneous set of illnesses but rather to a broad group of widely varying conditions (Saker, Lee, Cannito, Gilmore, & Campbell-Lendrum, 2004) that are transmitted from a person, animal or inanimate source to another person either directly, with the assistance of a vector or by other means, while non-communicable diseases (NCDs) are diseases or conditions that affect individuals over an extensive period of time and for which there are no known causative agents that are transmitted from one affected individual to another (Daar et al., 2007). If diseases are infectious, then they present in a pandemic (e.g. H1N1 influenza), epidemic (e.g. measles), or endemic (e.g. malaria) form, while if non-communicable as acute (e.g. accidents) or chronic (e.g. cancer) form (Roger, 2005).

For the purpose of this blog entry infectious diseases will be classified according to the causative agent, namely: Bacterial (e.g. Tuberculosis), parasitic (e.g. Malaria) and viral (e.g. HIV/AIDS).

Management strategies and progress against infectious diseases

Generally, control of infectious diseases can be directed either at the agent, the route of transmission, the host or the environment and sometimes a combination of the control strategies (Roger, 2005). The general methods of control are summarized in Figure 1 below.

Prevention principles

We will now focus on the progress and management efforts that have been used to combat infectious diseases but mainly drawing management strategies from HIV/AIDS, Malaria and Tuberculosis.

HIV/AIDS

Progress

On the global context the annual number of people newly infected and dying from HIV has greatly reduced, see Figure 2 below.

HIV progress

Based on the MDG Report 2015 (UNDP, 2015), in the last 15 years, Africa has made significant strides in combating HIV/AIDS. The progress in reducing the mortality rate and the pandemic status of HIV/AIDS has encompassed all five of Africa’s geographical sub-regions, see Table 1 below.

HIV in Africa progress

Management

Progress in HIV/AIDS rests on a number of factors including: improvement in testing, counselling and access to antiretroviral therapy; the reduction in mother-to-child transmission; the increase in prevention through the use of condoms and treatment as prevention; and the improvement in the general awareness and knowledge of the disease, including a better understanding of the link between HIV and tuberculosis. Engaging men in the fight against HIV also proved a winning strategy (UNDP, 2015).

Malaria

Progress

In the World Malaria Report 2015 (WHO, 2015f) it is highlighted that there has been a dramatic decline in the global malaria burden over the past 15 years (2000-2015) whereby 57 countries have reduced their malaria cases by 75%, with the global incidence and mortality rate reducing by 37% and 60%, respectively, see figure 3 below.

Malaria incidence

Management

Progress was made possible through the massive rollout of effective prevention and treatment tools: Vector control interventions, use of insecticide-treated bed-nets, quality-assured artemisinin-based combination therapy and rapid diagnostic tests have expanded in Africa over the past 10 years. However, specific efforts to protect pregnant women and children against malaria are progressing rather slowly (WHO, 2015f).

Tuberculosis

Progress

The MDG target of halting and reversing TB incidence by 2015 was achieved globally, in all six WHO regions and in 16 of the 22 high TB burden countries (WHO, 2015b). Since 2000, the global community has experienced a downward trend in tuberculosis prevalence, incidence and death rates (WHO, 2015b) see Figure 5 below.

TB trends

Management

The changes in tuberculosis prevalence and death rates mirror the rate of detection and treatment success under the DOTS approach which remains at the heart of Stop TB strategy which entails: Political commitment with increased and sustained financing; Case detection through quality-assured bacteriology; standardized treatment, with supervision and patient support; an effective drug supply and management system and Monitoring and evaluation system, and impact measurement (WHO, 2015d). Between 2000 and 2014, TB treatment alone saved 35 million lives among HIV-negative people; TB treatment and antiretroviral therapy saved an additional 8 million lives among HIV-positive people (WHO, 2015b).

Investment in infectious and non-communicable diseases 2000-2014

Development assistance for health (DAH) Disbursement

In 2000, the international community put global health high on the development agenda. Three distinct Millennium Development Goals focused on health issues in the developing world. At the forefront was the fight against child mortality, maternal mortality, and three infectious diseases: HIV/AIDS, malaria, and tuberculosis (TB). The formation of the MDGs was followed by major increases in global health financing flows. Rapid growth took hold from 2000 to 2010, following the launch of the MDGs. From 2013 to 2014, Development assistance for health (DAH) dropped by 1.6% (IHME, 2014). From the purchase of antiretroviral drugs and long-lasting insecticide-treated nets to support for disease-specific planning and programming, DAH has funded an array of activities in pursuit of MDGs 4, 5, and 6  with the very least proportion (1.48% of total) directed towards the non-communicable diseases.

Figure 8 below shows that UN agencies, including UNICEF, WHO, and UNAIDS, concentrated their DAH contributions most substantially on Maternal, newborn and child health (43.6%), but also supported work on other infectious diseases (11.3%), HIV/AIDS (6.6%), and Sector wide approaches/health sector support (5.3%), and to a minor extent non-communicable disease (1.8%), tuberculosis (1.1%), and malaria (0.9%). The investment on non-communicable diseases is generally low across all funding sources as compared to the MDG focus areas diseases.

DAH for health focus

Interestingly, the WHO programme budget allocation for communicable/infectious diseases has been declining for the past 2 financial years while the programme budget for non-communicable has been increasing see Table 2 below.

WHO budeget

Change in disease burden from infectious to non-communicable diseases?

Historically, infectious diseases (IDs) have been the most important contributor to human morbidity and mortality (WHO, 2002) until recent times, when dominance has shifted to non-communicable diseases (Beaglehole & Bonita, 2008) as shown in Figure 9 below. This dominance of NCDs could be as a result of low investment as we have established from the previous section above.

Projected deaths

Non-communicable diseases (NCDs) are one of the major health and development challenges of the 21st century, in terms of both the human suffering they cause and the harm they inflict on the socioeconomic  fabric of countries (Suhrcke, Nugent, Stuckler, & Rocco, 2006), particularly low-and middle-income countries (WHO, 2014), see Figure 10.

Chronic diseases

The number of deaths from non-communicable diseases is double the number of deaths that result from a combination of infectious diseases (including HIV/AIDS, tuberculosis and malaria), maternal and perinatal conditions, and nutritional deficiencies (Daar et al., 2007). Over the coming decades the burden from NCDs is projected to rise particularly fast in the developing world (WHO, 2005a). Non-communicable diseases (NCDs) are now recognized as a development issue.

Conclusion: Is there a necessity for WHO to shift from infectious diseases?

This far we can actually conclusively agree that the success in the progress of the MDG diseases (HIV/AIDS, Malaria and Tuberculosis) was as a result of heavy financial investment from several sources as development assistance for health (DAH) (IHME, 2014). This clearly confirms the fact that health interventions are largely based around economics; disease with the greatest perceived burden tend to be where most resources are targeted. This clearly affirms the statement, “Many may suggest that infectious diseases are suitably managed in terms of financial investment

The huge emphasis placed on the burden created by HIV/AIDS, Malaria and Tuberculosis in the original 1990 Global Burden of disease study by (Murray & Lopez, 1996) had the unintended consequence, over the last two decades, of committing the majority of resources towards combating these three diseases, “ignoring” investment in the other diseases and of major concern resulting to the rising trend in non-communicable diseases.

The increased investment in non-communicable diseases by the World Health Organisation and statement by Dr. Margaret Chan (Director General of WHO) which stated, “Worldwide, NCDs have overtaken infectious diseases as the leading cause of mortality. This shift challenges traditional development thinking, which has long focused primarily on infectious diseases and maternal and child mortality as priorities for international action. We continue to support this focus, but need to make space for additional challenges” (WHO, 2015e); certainly informs us that the shift in focus is a timely investment to address the rising challenge of non-communicable diseases but what is required of the WHO is to develop a balanced approach of tackling both infectious and non-communicable diseases.

References

Beaglehole, R., & Bonita, R. (2008). Global public health: a scorecard. Lancet, 372, 1988–1996. doi:DOI:10.1016/S0140-6736(08)61558-5

Daar, A. S., Singer, P. A., Leah Persad, D., Pramming, S. K., Matthews, D. R., Beaglehole, R., . . . Bell, J. (2007). Grand challenges in chronic non-communicable diseases. Nature, 450(7169), 494-496.  Retrieved from http://dx.doi.org/10.1038/450494a

IHME. (2014). Financing Global Health 2014: Shifts in Funding as the MDG Era Closes. Retrieved from Seattle, WA: http://www.healthdata.org/policy-report/financing-global-health-2014-shifts-funding-mdg-era-closes

Murray, C. A., & Lopez, A. D. (1996). The Global Burden of Disease: The Havard School of Public Health on behalf of The World Health Organisation and The World bank.

Roger, W. (2005). Communicable Disease Epidemiology and Control: A Global Perspective (Second ed.): Oxfordshire, U.K. ; Cambridge, Mass. : CABI Pub. .

Saker, L., Lee, K., Cannito, B., Gilmore, A., & Campbell-Lendrum, D. (2004). Globalization and infectious diseases: A review of the linkages. Retrieved from http://www.who.int/tdr/publications/documents/seb_topic3.pdf

Suhrcke, M., Nugent, R. A., Stuckler, D., & Rocco, L. (2006). Chronic Disease: An Economic Perspective. Retrieved from London: http://www.nature.com/nature/journal/v450/n7169/full/450494a.html

UNDP. (2015). MDG Report 2015: Lessons learned in implementing the MDGS. Retrieved from http://www.undp.org/content/dam/rba/docs/Reports/MDG%20Report%202015_ENG.pdf

WHO. (2002). World health report 2002. Retrieved from Geneva,: http://www.who.int/whr/2002/en/whr02_en.pdf?ua=1

WHO. (2005a). Preventing Chronic Diseases: A Vital Investment. Retrieved from Geneva: http://www.who.int/chp/chronic_disease_report/contents/en/

WHO. (2005b). Preventing Chronic diseases: a vital investment-Part one. Retrieved from http://www.who.int/chp/chronic_disease_report/contents/part1.pdf?ua=1

WHO. (2013). Proposed Programme Budget 2014-2015. Retrieved from http://apps.who.int/gb/ebwha/pdf_files/WHA66/A66_7-en.pdf

WHO. (2014). Global status report on noncommunicable diseases 2014.  Retrieved from http://www.who.int/nmh/publications/ncd-status-report-2014/en/

WHO. (2015a). Global health sector response to HIV, 2000-2015: Focus on innovations in Africa. Retrieved from Geneva: http://apps.who.int/iris/bitstream/10665/198148/1/WHO_HIV_2015.40_eng.pdf

WHO. (2015b). Global tuberculosis report 2015. Retrieved from France: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1

WHO. (2015c). Proposed programme budget 2016-2017. Retrieved from http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_7-en.pdf

WHO. (2015d). Tuberculosis (TB): The five elements of DOTS.   Retrieved from http://www.who.int/tb/dots/whatisdots/en/

WHO. (2015e). WHO Director General addresses the place of noncommunicable diseases in strategies and agendas. Director-General.  Retrieved from http://www.who.int/dg/speeches/2015/ncd-development-cooperation/en/

WHO. (2015f). World malaria report 2015. Retrieved from Geneva: http://apps.who.int/iris/bitstream/10665/200018/1/9789241565158_eng.pdf

7

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories

MRSA in humans and animals in Kenya (an overview)

MRSA in humans and animals in Kenya (an overview)

MRSA in humans and animals in Kenya (an overview)

Introduction

Staphylococcus aureus is an important bacteria because of its ability to cause a wide range of diseases and adapt to diverse environments. The bacteria causes infection to both humans and animals by colonizing their skin, skin glands and mucous membranes, resulting to septicemia, meningitis, and arthritis in man and mastitis in the bovine, as well as poultry limb infections [1]. Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staphyloccocal bacteria that is resistant to beta-lactams. It is a common cause of healthcare-associated infections in both developed and developing countries, though limited information is available from the latter [2] [3].

MRSA Resistance mechanisms

The resistance of S. aureus against methicillin is caused by expression of Penicillin binding protein 2A (PBP2A) encoded by the mecA gene [4]. PBP2A has low affinity for beta-lactam antibiotics such as amoxicillin, methicillin and oxacillin, rendering these antibiotics ineffective in treating infections caused by Staphylococcus aureus. Lately, a new methicillin resistance mechanism gene, mecC has been reported in isolates from humans and animals [5]. This therefore means that MRSA is not only associated with prior exposure to a health care facility but also raises concerns for infections originating from the community and veterinary species, and there is a possibility of a cross-infection with animals being potential sources of MRSA infection to humans [6].

MRSA the Kenyan perspective

In 1997, documented rates of MRSA in Kenya were 28 percent of all S. aureus tested in city hospitals. A separate hospital-based study during the same year found the prevalence of MRSA to be 40 percent of all S. aureus infections. In 2006, MRSA was found in 33 percent of S. aureus isolates at another hospital based study [2]. Resistance, therefore, may indicate illegal use of drugs by the public. A survey of farmers in Kenya found that the majority conflated treatment with prevention, effectively replacing hygiene and feeding practices as standard disease prevention with disease treatment [2]. Patterns of resistant Staphylococcus aureus in cattle imply a significant difference in resistance profiles of large and small scale farms, with smaller producers using nearly twice the amount of antibiotics per animal compared with larger producers [7]. The prevalence of multidrug resistance, at 34 percent on small farms, was likewise almost double the rate found at large farms [2].

The dillemma

There is evidence that MRSA infection increases the risk of mortality, morbidity, medical care costs and loss of productivity. The increased medical care costs accrued directly as expenses caused by extension of hospital stay, additional diagnostic or therapeutic procedures, and additional antibiotic use while loss of productivity is due to absence from work during hospitalization. At the same time, published data  concerning  the  antibiotic  susceptibility  patterns  of  MRSA  in  sub-Saharan  Africa  are extremely limited, and few studies on it have been conducted in Kenya [2] [3]. Many studies on MRSA in Kenya are mainly cross-sectional with a focus to determine the prevalence, identifying the antibiotic resistance but they have not focused on the zoonotic significance of MRSA. There is need to understand on how the resistance to MRSA is changing over time so as to be able to clearly visualize the mechanism and transfer of resistance genes in the population [3].

Zoonotic directionality of resistance

It is therefore important not only to determine the antibiotic resistance, but also determine what and who is causing this resistance in humans and animals belonging to the same household and also determine the temporal and spatial change of this resistance over time. This is because, by understanding the dynamics and the epidemiology of MRSA infection over time it will be possible to develop more informed prevention and control strategies, develop more sound policies including education on the rational use of antibiotics to the public.  At the same time it is important to  fill the knowledge gap [3] (especially from a developing country setting) in the zoonotic directionality of MRSA.

References 

Waldvogel, F.A., Staphylococcus aureus, in Principles and practices of infectious disease, G.L. Mandell, D. R.G., and B. J.E., Editors. 2000, Pennsylvania, USA.: Churchill Livingstone, Philadelphia, . p. 1754-1777.

Global Antibiotic Resistance Partnership-Kenya Working Group, Situation Analysis and Recommendations: Antibiotic Use and Resistance in Kenya, S. Kariuki, Editor. 2011, Center for Disease Dynamics, Economics & Policy: Washington, DC and New Delhi.

WHO, Antimicrobial resistance global report on surveillance. 2014. p. 1-256.

Wielders, C.L.C., et al., mecA Gene Is Widely Disseminated in Staphylococcus aureus Population. J. Clin. Microbiol., 2002. 40(11): p. 3970-3975.

Paterson, G.K., et al., The newly described mecA homologue, mecALGA251, is present in methicillin-resistant Staphylococcus aureus isolates from a diverse range of host species. J. Antimicrob. Chemother., 2012. 67(12): p. 2809-2813.

Ferreira, J.P., et al., Transmission of MRSA between Companion Animals and Infected Human Patients Presenting to Outpatient Medical Care Facilities. PLoS ONE, 2011. 6(11): p. e26978.

Shitandi, A. and A. Sternesjö, Prevalence of Multidrug Resistant Staphylococcus aureus in Milk from Large and Small Scale Producers in Kenya. Journal of Dairy Science, 2004. 87: p. 4145-4149.

7

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories

Ebola a wake up call for Ecohealth Alliance

Ebola a wake up call for Ecohealth Alliance

Ebola a wake up call for Ecohealth Alliance

Peter Daszak, President Ecohealth Alliance, in this short video reiterates on how Ebola was a wake up call for them and that their research at the Ecohealth alliance has shown that emergence of disease is a result of anthropogenic actions of man to the environment. Further he states that governments are more concerned about economics than conservation, but when conservation threats are packaged as economic threats then this triggers change, he gives an example of China closing down the wildlife market (which they did as a result of safeguarding health and not conservation per se).

View the four minute video here: https://m.youtube.com/watch?v=KLY3jXXs3ZQ&feature=youtu.be

7

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories

Oral cysticercosis: A contribution of dentists & clinicians to One Health?

Oral cysticercosis: A contribution of dentists & clinicians to One Health?

Oral cysticercosis: A contribution of dentists & clinicians to One Health?

Historical account

Cysticercosis was first described by Johannes Udalric Rumler in 1555 but the connection between tapeworms and cysticercosis in man was still a mystery. In 1855, Kuchenmaister established that human cysticercosis is indeed caused by the larval stage, Cysticercus cellulosae, of the pork tapeworm, Taenia solium[14].

Epidemiology

Cysticercosis is prevalent in several parts of the world. It is endemic and one of the leading causes of acquired epilepsy[10] in developing countries, mainly in parts of Asia, Africa, Latin America and Eastern Europe. This is especially in those areas with uncontrolled free range pig production, poor sanitation and where humans and animals live in close contact[1]. Its incidence is also increasing in developed countries as a result of migration of infected persons and frequent travel to and from endemic areas[27].

In man, cysticercosis frequently involves many parts of the body including the brain (causing fatal neurocysticercosis), subcutaneous tissues, heart, liver, lungs, peritoneum, skeletal muscles and the eye. Although oral involvement by cysticercosis is common in swine, this location is a very rare occurrence in humans[17, 27, 1] where it presents as a component of disseminated cysticercosis and often a diagnostic challenge to clinicians [14].

A literature review conducted in 2012 by Krishnamoorthy and colleagues  [14], revealed 69 cases of oral cysticercosis characterized by a cystic swelling as the only evidence of the disease. They further found that any region of the oral cavity can be involved but review of literature suggested that the tongue was the preferred site comprising 46.37% of the 69 cases, followed by labial and buccal mucosa, with one case documented involving the gingival tissue from India [17]. However, some authors postulate that the muscular activity and high metabolic rate of the oral region may prevent lodging of the cysticerci in the tongue[5]. Other authors have also noted that intraorally, the favored sites for the development of cysticerci are the tongue, labial mucosa (lips), buccal mucosa (cheeks) and the floor of the mouth, however, correct and precise diagnosis is infrequently established [20, 6, 23, 13, 29, 7, 12]

How does man get infected?

Man is the definitive host for the adult pork tapeworm (Taenia solium) while the pig serves as an intermediate host. Human beings are infected by either:

  1. Eating uncooked, partially cooked or inadequately frozen pork containing viable Cysticercus cellulosae.
  2. Ingesting food or water contaminated by infected human faeces containing Taenia solium eggs which further explains cases of cysticercosis in vegetarians [11]
  3. Autoinfection by regurgitation of eggs into the stomach after reverse peristalsis[20, 3, 24]

In the human body the larval form (Cysticercus cellulosae) penetrates the intestinal mucosa and is then distributed through the blood vessels and lymphatics to the various parts of the body where they develop into cysticerci completing the life cycle.

What are the clinical signs?

In humans cysticercosis can develop in various organs and tissues. The larval form (Cysticercus cellulosae) commonly presents as a cyst in the cerebral tissue (brain), meninges, subcutaneous tissue, muscle and the eye [3, 19, 13, 15]. However, it is not commonly considered in the diagnosis of swellings of the maxillofacial region including the oral cavity and cheek muscles.

Most oral presentations of cysticercosis are in the form of painless, well-circumscribed, soft swellings or cystic nodules[12], that may persist or rupture and heal uneventfully[11]. Therefore, oral cysticercosis is a diagnostic challenge to a clinician due to:

  1. The condition mimics other oral nodular lesions like mucoceles, or a benign tumor of mesenchymal origin, such as a lipoma, fibroma, hemangioma, granular cell tumor, or a minor salivary gland adenoma[22]. However, the high intraluminal pressure in oral cysticercosis helps to differentiate it from lipoma and hemangioma.
  2. Cysticercosis is rarely included in the pre-operative differential diagnosis due to relative rarity of the lesion, inadequate knowledge of oral manifestations of parasitic infections and negligence while taking medical history[26].

Generally, the clinical symptoms of cysticercosis depend on the site and the number of cysticerci in the body. Cysticerci are well tolerated in the tissues when they are alive but evoke an inflammatory reaction in the surrounding tissue on  death. During invasion there may be no symptoms or mild muscular pain and fever. Central nervous system involvement may result to the potentially fatal neuro-cysticercosis[9].

Examples of oral cysticercosis case presentation and presumptive diagnosis: 

1. JoshiExample one, Joshi and colleagues (2014)[12]: An 18 year old male from Central India with an asymptomatic solitary cystic nodule in the right mucobuccal fold of upper arch. The patient reported that the lesion was present since 5-6 years with no associated pain. Intra oral examination revealed that the nodule as spherical in shape, 2 x 2 cm in size, firm, smooth surfaced and mobile. Noted in the alveolar mucosa mainly in mucobuccal fold of maxillary right canine region. There was no much change in the size and other features of the lesion in due course. The patient was otherwise healthy without any systemic signs and symptoms.

Example two, Bhatia and colleagues (2014)[1]: A case of eight year old Hindu female and a resident of a slum in Mumbai. The patient came with a swelling inside the oral cavity on the right buccal mucosa since one year which gradually increased in size. On local examination the swelling was non tender, firm and mobile measuring 1 x 0.5cm.

WanjariExample three, Wanjari and colleages (2013)[28]: Clinical presentation for both (2) cases was of diffuse, nontender, soft to fluctuant swelling. Case 1 showed involvement of the right cheek in the lower third of the face in line with the outer canthus of the right eye; however, intraorally overlying mucosa was intact and normal in colour. While case 2 revealed involvement of right labial mucosa in relation to maxillary right anterior region. No submandibular or cervical lymphadenopathy was detected in both cases.

Example four, Venkatraman and colleagues (2013)[27]: A 23 year old male presented with a swelling on the right lateral border of the tongue. The patient reported that the lesion was present since 4 years with no associated pain. Intra oral examination revealed that the lesion was spherical in shape, 2×2 cm in size, firm, compressible, smooth surfaced and mobile within the soft tissue of the tongue.

ChunturiExample five, Chunduri and colleagues(2013) [2]: A 17 year old Indian male presented with a nodule in the right lower lip. Clinical examination revealed a well circumscribed, mobile nodule approximately 1.5 cm in diameter with intact overlying mucosa. The lesion was painless and had been present for about six months, and was slowly growing.

Nervos SantosExample six, Neves Santos and colleagues (2013)[21]: A 21-year-old woman from Poções County (Bahia, Brazil) reported to a private dental center with the chief complaint of a painless nodule on the right side of her tongue that had been present for the past two years. The nodule had increased in size to approximately 3.5 cm in maximum diameter, and clinical examination showed a firm nodule that was covered with normal mucosa. No cervical or submandibular lymphadenopathy was observed. A complete blood count, liver function tests and renal function tests were all normal. A preliminary diagnosis of lipoma was made.

 

 

Krishnamoorthy

Example seven, Krishnamoorthy and colleagues (2012)[14]: A 12-year-old girl with a nodular swelling on the lower lip. She first noticed it 2 months ago. The swelling was painless, remained unchanged in size, and caused a little difficulty while eating and talking. On examination there was a solitary, spherical, well-defined swelling in the lower labial mucosa present on the left side of the midline which measured approximately 1.5 X 1.5 cm. The mucosa over the swelling was normal. On palpation it was not tender, but was tense and nonfluctuant. Differential diagnoses of mucocele, lipoma, and fibroma were considered.

Diagnosis of oral cysticercosis  

Diagnosis of human oral cysticercosis (including other forms of tissue cysticercosis) is impaired by its polymorphic clinical presentations. Excisional biopsy coupled with sections stained with Haematoxylin & Eosin, is the only confirmatory diagnostic procedure for the condition, which demonstrates the presence of the larva in the tissue or the scolex in the cystic lesion. However, other investigations must be considered to detect the disease in the diverse tissues that may be affected, using: Fine Needle Aspiration (FNA), serology, radiologic imaging techniques such as Computer Tomography (CT) or Magnet Resonance Imaging (MRI) and advanced molecular techniques as tools for conformational diagnosis[5][7].

Criteria for diagnosing oral cysticercosis as proposed by Krishnamoorthy and colleagues is: [14]:

  • A compatible clinical presentation
  • FNA aspirated material showing a speck of pearly white content also by[17, 27]
  • Histopathologic demonstration of the parasite on biopsy
  • Cystic lesions with scolex on imaging (muscular cysticercosis)
  • Positive epidemiological factors like household contact, endemic region or travel to or from an endemic area

Examples of oral cysticercosis definitive diagnoses: 

JoshiExample one, Joshi and colleagues (2014)[12]: Microscopically, the excised tissue showed a thin fibrous connective tissue capsule adjacent to a cystic cavity containing a duct like tubal segments that was lined by a homogeneous membrane typical of cysticercosis cellulosae (larval form of Taenia solium); Cyst wall and outer fibrous tissue was presenting in many papillary projections along with numerous inflammatory cell infiltrations and macrophages.

BhatiaExample two, Bhatia and colleagues (2014)[1]: External fibrous capsule with mononuclear cell infiltrate comprised of lymphocytes, histocytes and plasma cells. A double layered membrane consisting of an outer acellular hyaline eosinophilic layer and an inner sparsely cellular layer with aggregates of eosinophils was seen. The cyst contained larval form of T. Solium. The cephalic extremity of larva (scolex) with suckers could be identified suggesting the diagnosis of cysticercosis of right buccal mucosa.

WanjariExample three, Wanjari and colleagues (2013)[28]: Histopathological examination of excisional biopsy specimen revealed external dense, fibrous capsule derived from host tissue surrounding a cystic cavity which contained larval stage of T solium-cysticercus cellulosae. capsule showed intense inflammatory infiltrate consisting of plasma cells and few eosinophils. The larva consisted of a scolex, where suckers and duct-like invaginated segment could be identified at the caudal end. A digitiform coating of homogenous eosinophillic membrane was evident lining the cystic area. A final diagnosis of oral cysticercosis was made. MRI and CT scan were negative which ruled out neurocysticercosis (NCC).

Example four, Venkatramana and colleagues (2013)[27]: Histopathology of the excised tissue revealed a thin capsule of fibrous connective tissue surrounding a cystic cavity, which contained cysticercosis cellulosae (larval form of Taenia solium). The larva composed of a duct like tubal segments that was lined by a homogeneous membrane. Cyst wall and outer fibrous tissue was infiltrated with numerous inflammatory cells, macrophages and few foreign body type giant cells. Based on these findings, a diagnosis of cysticercosis was made

ChunduriExample five, Chunduri and colleagues (2013[2]: Microscopic examination revealed double glycoprotein membrane tissue surrounding a cystic cavity which contained Cysticercus cellulosae. The capsule showed intense inflammatory infiltrate, consisting mainly of lymphocytes and plasma cells. The larva was composed of a scolex, where a sucker could be identified, and a duct-like invaginated segment at the caudal end. No areas of dystrophic calcification were present in the specimen. Based on these findings, a diagnosis of cysticercosis was made.

Neves SantosExample six, Neves Santos and colleagues (2012)[21]: histological sections revealed the presence of a cystic lesion containing a serrated larva (C. cellulosae) with a cuticle and well-defined areolar and cellular layers as well as a cystic capsule exhibiting predominantly mononuclear inflammation. The final diagnosis was cysticercosis of the tongue.

KrishnamoorthyExample seven, Krishnamoorthy and colleagues (2012)[14]: A fine-needle aspiration (FNA) was performed. The aspirate was a clear fluid but the report was not conclusive. Hence the lesion was excised under local anesthesia which was a smooth well-encapsulated mass. Hematoxylline and eosin (H/E) stained sections showed a cystic mass containing the cysticercus cellulosae surrounded by dense fibrous capsule infiltrated with inflammatory cells, mainly lymphocytes and plasma cells. The inner aspect of the capsule was a double-layered membrane in which larval form of T. solium were seen. Larva showed the presence of suckers and caudal to it duct-like invagination segment lined by homogenous membrane. No areas of dystrophic calcifications were present in the tissue specimen. The final diagnosis of cysticercosis of the lip was made.

Differential diagnoses for oral cysticercosis

Oral cystucercosis is usually misdiagnosed as a mucocele, sialocyst or a benign tumor of mesenchymal origin such as lipoma, fibroma, hemangioma, lymphangioma, granular cell tumor  [16, 27], benign salivary gland neoplasms[8] and parasitic cysts e.g. hydatid cyst. Stool examination is usually carried out to rule out parasitic cysts [28].

Treatment

Oral cysticerci, being usually localized and superficial lesions, are easy to excise and have good prognosis. Simple surgical excision is often all that is required to ensure complete removal of the lesion without any postoperative complications in such cases[5]. Lesions involving the muscles like the masseter may be treated conservatively with antiparasitic therapy[18]. Unlike the neurocysticercosis or orbital cysticercosis which are severe in their clinical presentations, the oral cysticercosis are usually well tolerated. However, it is important to exclude the presence of the parasite in other sites through a detailed case study and systematic investigations [14]. Praziquantel and albendazole are used to treat cysticercosis, especially in patient with disseminated cysticercosis or where surgical excision is risky or not possible, such as in neurocysticercosis[4].

Control and prevention

Transmitted via the orofecal route, cysticercosis is potentially eradicable. To prevent and eradicate human cysticercosis supportive measures such as improvement in the sanitary conditions, pork inspection, consumption of boiled water, well washed vegetables, mass education about personal hygiene should be undertaken along with medical treatment (by a registered and approved medical practitioner) which includes larvicidal drugs, corticosteroids, and surgical procedure for removal of the cyst[25, 28].

The role of the dental clinician?

The illustrations above clearly tell us the critical role that clinicians and especially dentists have in the control  of not only oral cysticercosis but cysticercosis as a Neglected Tropical Disease. The patient diagnosis of oral cysticercosis could act as a “sentinel” and insight to further investigate and control the problem in the family or community at large.

It is clear that oral cysticercosis should be considered in the differential diagnosis of intraoral solitary swellings especially in endemic areas. In endemic countries a lesion can be first referred for a FNA which is cost-effective, quick, and reliable. Expensive investigations, like immunological tests and CT, can be undertaken only in the absence of a definitive pathological diagnosis. As much as the histopathological findings of the excised swelling are diagnostic of the lesion a detailed evaluation should be done to exclude the presence of the parasite at other sites[14, 2].

References

  1. Bhatia, V., O., Natekar, A., A., and Valand, A., G., Paediatric Oral Cysticercosis: A Misdiagnosed and a Rare Entity. International Journal of Oral & Maxillofacial Pathology., 2014. 5(2): p. 26-28.
  2. Chunduri, N., S., Goteki, V., Gelli, V., and Madasu, K., Case Report: Oral Cysticercosis. SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH, 2013. 44(2).
  3. De Souza, P.E., Barreto, D.C., Fonseca, L.M., de Paula, A.M., Silva, E.C., and Gomez, R.S., Cysticercosis of the Oral Cavity: Report of Seven Cases. Oral Dis, 2000. 6: p. 253-5.
  4. Del Brutto, O.H., Sotelo, J., and Roman, G.C., Therapy for Neurocysticercosis: A Reappraisal. Clin Infect Dis, 1993. 17: p. 30-5.
  5. Delgado-Azañero, W.A., Mosqueda-Taylor, A., and Carlos-Bregni, R., Oral Cysticercosis: A Collaborative Study of 16 Cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007. 103: p. 528-33.
  6. Dhaif, G.A. and Al-Hadi, A.A., Oral Cysticercosis: A Case Report. Saudi Dental J 2000. 2: p. 100-2.
  7. Dysanoor, S. and Pol, J., A Solitary Facial Nodular Swelling: A Case Report of Intramuscular Cysticercosis in Buccinator Muscle. Asian Pac J Trop Dis, 2013. 3(3): p. 235-9.
  8. Garcia, H.H. and Del Brutto, O.H., Taenia Solium Cysticercosis. Infect Dis Clin North Am, 2000. 14: p. 97-119.
  9. Garcia, H.H., Evans, C.A.W., and Nash, T.E., Current Consensus Guidelines for Treatment of Cysticercosis. Clin Microbiol Rev, 2002. 15: p. 747-56.
  10. Jay, A., Dhanda, J., and Peter, L., Short Communication-Oral Cysticercosis. Br J Oral Maxillofac Surg, 2007. 45: p. 331-4.
  11. Jay, A., Dhanda, J., Chiodini, P.L., Woodrow, C.J., Farthing, P.M., Evans, J., and Jager, H.R., Oral Cysticercosis. Br J Oral Maxillofac Surg, 2007. 45(4): p. 331-4.
  12. Joshi, J., Sharanesha, M.B., Jatwa, R., and Khetrapal, S., Oral Cysticercosis: A Diagnostic Difficulty. J Clin Diagn Res, 2014. 8(10): p. ZD24-5.
  13. Junior, H.M., Melo, F., M.R., and Nogueira, d., Santos L.A., Oral Cysticercosis. Braz J Oral Sci, 2006. 5: p. 1109-11.
  14. Krishnamoorthy, B., Suma, G.N., Dhillon, M., Srivastava, S., Sharma, M.L., and Malik, S.S., Encysted Tenia Solium Larva of Oral Cavity: Case Report with Review of Literature. Contemp Clin Dent, 2012. 3(Suppl 2): p. S228-32.
  15. Lee, K.H., Cepeda, L., and Miller, M., Mucoceles Not-Oral Cysticercosis and Minor Salivary Gland Adenocarcinoma: Two Case Reports. Dermatol Online J 2009. 15(S).
  16. Mahajan, S., Agrawal, P., Datarkar, A., Datarkar, and Borle, R., Oral Cysticercosis: A Case Report. J Maxillofac Oral Surg, 2009. 8(1): p. 85-87.
  17. Mazhari, N.J., Kumar, N., and Jain, S., Cysticercosis of the Oral Mucosa: Aspiration Cytologic Diagnosis. J Oral Pathol Med, 2001. 30: p. 187-9.
  18. Mittal, A., Das, D., Iyer, N., Nagaraj, J., and Gupta, M., Massester Cysticercosis-a Rare Case Diagnosed on Ultrasound. Dentomaxillofac Radiol, 2008. 37(113-16).
  19. Mohan, H., Infectious and Parasitic Diseases, in Textbook of Pathology, Mohan, P. and Mohan, T., Editors. 2005, Jaypee Brothers Medical Publishers Ltd: New Delhi, India. p. 195-6.
  20. Mukheh, S., Kacker, S.K., and Kapilla, K., Cysticercosis of the Oral Cavity—a Clinic Pathological Study of Ten and a Half Years. JIDA, 1986. 58: p. 257-9.
  21. Neves Santos, F., Neves Santos Soares, F., Leal Macedo, C., Oliveira de Souza, R., Rode Santos, A., Araújo Silva Gurgel, C., and Luciano Neves Santos, F., A Brazilian Case of Tongue Cysticercosis. Advances in Infectious Diseases, 2012. 02(04): p. 106-109.
  22. Nigam, S., Singh, T., Mishra, A., and Chaturvedi, u., Oral Cystivercosis-Report of Six Cases. 2000.
  23. Nigam, S., Singh, T., Mishra, A., and Chaturvedi, K.U., Oral Cysticercosis–Report of Six Cases. Rev Inst Med Trop Sao Paulo, 2005. 47(2): p. 95-8.
  24. Patel, K., Shah, M., and Patel, B., Subcutaneous Oral Cysticercosis. Natl J Community Med, 2011. 2: p. 311-13.
  25. Ribeiro, A.C., Luvizotto, M., Soubhia, A.M., Castro, A., and Paulo, A., Oral Cysticercosis: Case Report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007. 104: p. 56-8.
  26. Singh, S., Chhabra, S., Aggarwal, G., Karla, R., Duhan, A., and Sen, R., Oral Cysticercosis- a Rare Presentation. Asian Pacific Journal of Tropical Medicine, 2011: p. 587-8.
  27. Venkatraman, J., Jain, A., and Parmar, P., Oral Cysticercosis-a Reare Case Report. Int J Cur Res Rev, 2013. 5(22): p. 89-93.
  28. Wanjari, S.P., Patidar, K.A., Parwani, R.N., and Tekade, S.A., Oral Cysticercosis: A Clinical Dilemma. BMJ Case Rep, 2013. 2013.
  29. Wilson, A., Mosqueda, A., Carlos, R., Antonio, M., and Contreras, E., Oral Cysticercosis: A Collab¬Orative Study of 16 Cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007. 103: p. 528-33.
7

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories

Brief overview of bovine brucellosis: The Kenyan perspective

Brief overview of bovine brucellosis: The Kenyan perspective

Brief overview of bovine brucellosis: The Kenyan perspective

Introduction

Brucellosis is the most common and widespread of all bacterial zoonotic infections affecting man, livestock and wild animals (OIE., 2012; Corbel., 2006 and FAO., 2003) with significant socio-economic impacts and human suffering in endemic areas (Young., 1995; Boschiroli et al., 2001; McDermott., 2013). In Kenya, the nationwide prevalence of brucellosis in animals is unknown (ZDU., 2015) but the Zoonotic Disease Unit (ZDU) is in the process of determining the national prevalence and incidence through the current and ongoing study at Kajiado county in Kenya. Previous work by ZDU on brucellosis has been published on June this year 2015 as, “Sero-prevalence of Brucellosis in Humans and their Animals: A Linked Cross-sectional Study in Two Selected Counties in Kenya

Epidemiology

Bovine brucellosis, caused by Brucella abortus, is a contagious disease with a worldwide distribution, except in regions where it has been eradicated (Robinson., 2003). It is less often caused by Brucella melintesis and seldom by Brucella suis, all of which are intracellular, facultative, Gram-negative, coccobacilli or short rod bacteria (OIE., 2012) of which nine biotypes have been recognized (Radostits et al., 2000).

Transmission

As a herd problem, it is primarily spread by contact and ingestion of contaminated material (Boschiroli et al., 2001; Radostits et al., 2000), while spread between herds is facilitated by introduction of asymptomatic animals (Nicoletti., 2013). The primary routes of infection are through the mucous membranes of the conjunctiva, oral and nasal surfaces (Abernethy et al., 2006) and supposedly through vertical transmission or colostrum (Aparicio., 2013). Humans get infected by direct or indirect contact with infected animals, their products or by-products (Corbel., 2006; Dean et al., 2012; Karadzinska-Bislimovska et al., 2010) and therefore humans play a role in its persistence and transmission (Aparicio., 2013).

Risk factors

Susceptibility of cattle to Brucella abortus infection is influenced by: management factors such as artificial insemination (Boschiroli et al., 2001), herd sizes and population density; animal factors such as age, sex, reproductive status; and biological factors such as herd immunity (Crawford., 1990). Infection occurs in cattle of all ages but persists commonly in sexually mature animals (Radostits et al., 2000). Young animals are more resistant to infection and often clear infections but latent infections may occur (Walker., 1999).

Factors contributing to brucellosis in Kenya include:

  • The available data on brucellosis is not adequate enough to inform effective control processes.
  • The free range production system practiced in most parts of the country helps to maintain the disease in both animal and human populations
  • The cultures of some community that encourages consumption of raw livestock products e.g. whole blood an raw milk
  • Inadequate and non-sustainable resources for effective brucellosis control i.e. for the implementation of test and cull policy (currently not practiced); for skill improvement and equipping of the existing surveillance personnel/ staff; for the hiring of adequate skilled personnel
  • Livestock-wildlife interaction (especially during free grazing), cattle rustling and porous borders limiting control efforts
  • Inadequate diagnostic techniques which by extension do not give a true picture of Brucellosis presence/absence (the current study by ZDU will validate the existing testing kits and provide alternative, better and tested diagnostic options

Clinical features

In cattle it is manifested by elevated incidences of third trimester abortions (Crawford et al., 1990), placental retention, stillbirths, infertility, carpal hygromas (McDermott., 2002) and potential sterility in males (Halling and Boyle., 2002), resulting in huge negative economic impacts (Schelling et al., 2003; OIE., 2012). Clinical signs are not pathognomonic for the disease (Corbel., 2006) and therefore diagnosis is by demonstrating Brucella pathogens through laboratory techniques. The same organism also causes undulant fever in man (Mantur et al., 2007), which presents as febrile flu-like illness and is common among pastoralists in Africa (Seifert., 1996) and also Kenya (Muruki et al., 1994).

Diagnosis of bovine brucellosis

There are basically three main groups of diagnostic methods for detecting Brucella species: Identification of the agent, serological tests and other complementary tests. Identification of the agent can be achieved through microscopy, isolation and inoculation (OIE., 2012; Weidmann., 1991); Serology achieved through: Milk Ring Test-MRT, Serum agglutination Test-SAT, buffered Brucella antigen tests-BBATs, and Complement Fixation test-CFT (Radostits et al., 2000) while complementary tests used are: enzyme-linked immunosorbent assay-ELISA (Fadeel., 2006), fluorescence polarization assay-FPA and Polymerase Chain Reaction-PCR (Romero et al., 1995). For control strategies at national/local level, the BBATs as well as the ELISA and FPA, are suitable screening tests (OIE., 2012).

In Kenya the RBPT, ELISA and CFT are conducted at the central Veterinary Laboratories with prospects of starting PCR testing for brucellosis.

Treatment

Generally, treatment of infected livestock is not attempted because of the high rates of treatment failure, cost, (Walker., 1999; Nicoletti., 2013) and potential problems of residues to public safety when high doses of antimicrobials are used as chemotherapy. Man can be treated with a combination therapy of Doxycycline and Rifampicin antimicrobials, however, relapses may occur (Corbel., 2006).

Prevention and control of bovine brucellosis

This can be achieved through public health education and awareness among consumers and farmers on proper animal husbandry practices, sanitation and food-borne risks associated with brucellosis. Vaccinating all breeding animals to raise herd immunity (OIE., 2012). Strengthen and endorse strategies to control cross-border animal movement coupled with routine surveillance that provides accurate epidemiological information about the disease. Test, segregate and eliminate infected animals (Weidmann., 1991) but it should be noted that this approach is not a viable option in developing countries due to the high implementation costs.

Surveillance and control strategies for brucellosis available in Kenya:

  • Surveillance of brucellosis is carried out by Veterinary Epidemiology and Economics Unit (VEEU) team but this is restricted to seroprevalence studies of particular areas in Kenya. There are about 7 veterinarians in the VEEU unit each of whom is in charge of particular diseases but work hand in hand in diseases surveillance collaboratively.
  • Each county in Kenya has at least one veterinarian to implement disease control measures in that county
  • Laboratory infrastrusture which comprise of:
    •  National referral laboratories, namely: Central Veterinary Laboratories (CVL) at Kabete and the National Veterinary Quality Control Lab at Embakasi
    • Regional laboratories, namely: Nakuru (serves southern Rift Valley region), Kericho (serves Nyanza, Western, and western Rift Valley region), Eldoret (serves Northern Rift Valley region, which has a satellite lab at Lodwar), Karatina (serves the Central and Eastern regions, which have a satellite lab at Isiolo), Mariakani(serves Coast region, having two satellite labs at Ukunda and Witu) and Garissa (serves North Eastern region)
  • Brucellosis was included in the Integrated Diseases Surveillance and Reporting system on March 2011 (reported on a monthly basis)
  • On 17th June of 2011 (Legal notice No. 68), Brucellosis was gazetted as a notifiable disease in Kenya under the animal diseases act (Cap. 364). This means that all identified cases of brucellosis must be reported to the department of veterinary services. Prior to this gazettement, cases of brucellosis were not necessarily reported and therefore it was difficult to determine the occurrence, prevalence and spread nationwide.
  • Establishment of Disease Free Zones (DFZ): These are zones to be established around the country to be free from diseases such as: FMD, RVF, CBPP, Brucellosis, CCPP, PPR, BSE. This will be done in three zones. The first phase is currently on-going and the area for the first DFZ is the coastal area
  • Research conducted by various universities in Kenya such as University of Nairobi as part of Msc and PhD projects and by various research institutes such as Kenya Agricultural and Livestock Research organisation (KALRO-previously KARI) and the International livestock Research Institute (ILRI).
  • The Zoonotic Disease Unit (ZDU) which was set up in 2011 by the Ministry of Livestock Development (MoLD) and the Ministry of Public Health and Sanitation (MPHS) with the main objective of establishing and maintaining active collaboration at the animal, human and ecosystem interface towards better prevention and control of zoonotic diseases (learn more about the activities of ZDU, by clicking here)

 Impact of brucellosis on the Kenyan animal population

Analysis of passively collected data between the years 2003 to 2010 by the Zoonotic Disease Unit in Kenya demonstrate that brucellosis is wide spread throughout Kenya (ZDU., 2015) and that hundreds of Brucella-associated abortions in livestock are reported every year, suggesting that the disease is a major source of morbidity and mortality.

Economic losses due to brucellosis in Kenya are due to: abortion; birth of weak calves; reduced milk production; impaired fertility; major impediment to trade and export; loss of man hours, high treatment cost and government costs on research and surveillance schemes.

References

Abernethy D.A., Pfeiffer D.U., Watt R., Denny G.O., McCullough S. and McDowell S.W. (2006). Epidemiology of bovine brucellosis in Northern Ireland between 1990 and 2000. The Veterinary Record. 158: 21, 717-21

Aparicio E.D (2013). Epidemiology of brucellosis in domestic animals caused by Brucella melitensis, Brucella suis and Brucella abortus. Rev. sci. tech. Off. Int. Epiz, 2013, 32(1), 53-60

Boschiroli M.L., Foulongne V., O’Callaghan D. (2001). Brucellosis: a worldwide zoonosis. Curr Opin Microbiol 2001; 4:58-64

Corbel M. (2006). Brucellosis in Humans and Animals: FAO, OIE, WHO. Available at http://www.who.int/csr/resources/publications/deliberate/WHO_CDS_EPR_2006_7/en/ (Accessed on 8th June 2015)

Crawford R., Huber J., and Adams B. (1990). Epidemiology surveillance. K.E. Nelson J.R. Duncan., Editors, Animal Brucellosis,. CRC Press, pp. 131–151

Dean A.S., Crump L., Greter H., Schelling E., and Zinsstag J. (2012). Global Burden of Human Brucellosis: A Systematic Review of Disease Frequency. PLoS Negl Trop Dis 6(10): e1865. doi:10.1371/journal.pntd.0001865

Fadeel M.A., Wasfy M.O., Pimentel G., Klena J.D., Mahoney F.J., and Hajjeh R.A. (2006) Rapid enzyme-linked immunosorbent assay for the diagnosis of human brucellosis in surveillance and clinical settings in Egypt.  Saudi Med J. 2006 Jul;27(7):975-81.

Halling S.M. and Boyle S.M. (2002) Brucellosis. Veterinary Microbiology. 90, 19-183

Kadohira M., McDermott J.J., Shoukri M.M., and Kyule M.N. (1997). Variations in the prevalence of antibody to brucella infection in cattle by farm, area and district in Kenya. Epidemiology and Infection. 118(1), 35–41.

Karadzinska-Bislimovska J., Minov J., Mijakoski D., Stoleski S., and Todorov S. (2010). Brucellosis as an Occupational Disease in the Republic of Macedonia. Macedonian Journal of Medical Sciences. 2010 Sep 15; 3(3):251-256

Mantur B.G., Amarnath S.K., and Shinde R.S. (2007). Review of clinical and laboratory features of human Brucellosis. Indian J Med Microbiol;25:188-202.

Mcdermott J., Grace D., and Zinsstag (2013). Economics of brucellosis impact and control in low-income countries. Rev. sci. tech. Off. int. Epiz., 2013, 32 (1), 249-261

McDermott J.J., and Arimi S.M. (2002). Brucellosis in sub-Saharan Africa: epidemiology, control and impact. Veterinary Microbiology, 90(1-4), pp.111-134.

Muriuki S.M., McDermott J.J., Arimi S.M., Mugambi J.T. and Wamola I.A. (1997). Criteria for better detection of brucellosis in the Narok District of Kenya. East Africa Med. J. 74: 317 – 320.

Nicoletti P., (2013). Brucellosis in cattle. In the Merck Veterinary Manual online. Available at: http://www.merckvetmanual.com/mvm/reproductive_system/brucellosis_in_large_animals/brucellosis_in_cattle.html (Accessed on 24th June 2015)

Ogola E., Thumbi S., Osoro E., Munyua P., Omulo S., Mbatha P., Ochieng L., Marwanga D., Njeru I., Mbaabu M., Wanyoike S., and Njenga N. (2014). Sero-prevalence of Brucellosis in Humans and their Animals: A Linked Cross-sectional Study in Two Selected Counties in Kenya. Online J Public Health Inform. 2014; 6(1): e67. doi:  10.5210/ojphi.v6i1.5166

OIE-World Organisation for Animal Health (2012). Bovine brucellosis. In Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Available at: www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.04.03_BO VINE_BRUCELL.pdf (Accessed on 25 June 2015).

Pappas G., Papadimitriou P., Akritidis N., Christou L., and Tsianos V. (2006). The new global map of human brucellosis. Lancet Infect Dis 6: 91–99. doi: 10.1016/s1473-3099(06)70382-6

Radostitis E.,  Gay C.C., Blood D.G., and Hirchecliff K.W. (2000). Veterinary Medicine: a textbook of diseases of cattle, sheep, goats and horses, 9th edition., W.B. Saunders Company Ltd, London. Pp. 867-882

Robinson A. (2003): Guidelines for coordinated human and animal brucellosis surveillance. FAO animal production and health paper 156. Food and Agriculture Organisation of the United Nations, Rome

Schelling E., Dinguimbaye C., Daoud S., Nicoletti J., Boertin P., Tanner M. and Zinnstag J. (2003). Brucellosis and Q-fever seroprevalence of nomadic pastoralists and their livestock in Chad. Preventive Veterinary Medicine. 61,279–293.

Seifert S.N., (1996). Brucellosis. Tropical Animal Health. Kluwer Academic Publishers. Pp 356-368.

Sombroek W.C., Braun M.H., and van der Pour J.A. (1982). Explanatory Soil Map and Agro-climatic Zone Map of Kenya. Report E1. National Agricultural Laboratories, Soil Survey Unit, Nairobi, Kenya, 56 pp.

Walker R.L. (1999). Veterinary Microbiology. Blackwells Science. Cambridge, Massachusetts, pp. 196-203

Young E.J. (1995). An overview of human brucellosis. Clin Infect Dis 1995;21:283-290. Accessed at: http://www.ncbi.nlm.nih.gov/pubmed/8562733 (Accessed on 16th June 2015)

ZDU-Personal communication (2015). Epidemiologic and laboratory Assessment of the Burden of brucellosis in Kenya study (study still in progress)

ZDU. (2012). Brucellosis sero-prevalence study Kiambu, 2012-Dissemination of results Kiambu county. Accessed at  http://zdukenya.org/wp-content/uploads/2012/09/Brucellosis-study_Kiambu.pdf (Accessed on 17th June 2015)

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories

What are the alternatives for a Global One Health Governance Body?

What are the alternatives for a Global One Health Governance Body?

What are the alternatives for a Global One Health Governance Body?

Since there is no blueprint for making ‘One Health‘ operational, I agree with the Atlanta Report that the alternative of having a One Health governance body is to have a ‘One Health Global Guidance Group’-G3 that will provide neutrality, credibility and build on the existing international, regional and sub-national platforms, so as to find practicable approaches that factor in the needs of all “actors” in developed and developing worlds.

The proposed One Health Global Guidance Group will champion the concepts and goals of One Health and act as a facilitator and enabler and not a “government”. In my opinion the success of the guidance group will be through emphasizing the need for a bottom-up collaboration and catalyzing leadership at all levels since the ultimate responsibility lies within individual countries to develop a framework evolving from local issues by including community participation and building local capacity and avoid “a one size-fits it all approach.”

The proposed “soft governance” approach through a Global Guidance Group is a sound alternative built on existing individual country frameworks. I will also propose to have country “One Health ambassadors” who will work with the Global Guidance Group at the country level. These ambassadors should be volunteers from the Ministry of Health/Agriculture/Environment. As much as it is a sound alternative, let‘s now find out some of the factors that may encourage or discourage a truly global commitment to One Health in the next post.

References

Updates direct to your Email

Enter your email address to receive notifications of new posts and opportunities by email.

Join 7,243 other subscribers

Post categories